Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 2 × Breast Diseases × Aromatase Inhibitors × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Breast Neoplasms 28 Neoplasm Metastasis 2 Luminal B/HER2-negative Breast Cancer 1 Hormone Receptor Positive Breast Carcinoma 1 Hormonal Receptors Positive, HER2 Negative, Advanced Breast Cancer 1 Estrogen Receptor and/or Progesterone Receptor Positive 1 Bulbo-Spinal Atrophy, X-Linked 1 Breast Neoplasms, Male 1 Breast Diseases 1 Breast Cancer Female 1 Arthralgia 1 Advanced Breast Cancer 1

Interventions

pyrotinib 2 Trastuzumab 2 Letrozole 2 Docetaxel 2 figitumumab 1 exemestane 1 Zoledronic Acid 1 Vinorelbine 1 Lapatinib 1 Everolimus 1 Drug Evaluation 1 Cyclophosphamide 1 Aromatase Inhibitors 1 Anastrozole 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT03910712 2019-04-10

Pyrotinib

Peking Union Medical College Hospital

Phase 2 Unknown

Breast Diseases, Breast Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon ⚡